Testing a New Pulsed Field Ablation Device for Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new device that uses gentle electrical pulses (PFA) to treat prostate cancer without cutting or heat. It is for men with various risk levels who haven't had other prostate cancer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 45 or older, with a life expectancy of at least 10 years.
- Have low, intermediate, or high-risk prostate cancer (confirmed by biopsy and based on PSA, Gleason score, and stage).
- If you have higher-risk cancer (unfavorable intermediate or high), you must be willing to have your prostate removed 1 to 6 months after the study procedure.
- No prior treatment for prostate cancer (like surgery, radiation, or chemotherapy) and no other cancers in the past 5 years.
- No metal implants in your urethra, no severe claustrophobia (if you need an MRI), and no active urinary infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This trial tests a laser treatment that targets only the cancerous part of the prostate. It may be an option for men with intermediate-risk prostate cancer who do not want their entire prostate removed.
This study tests a new, less invasive treatment using targeted microwave ablation (TMA) to destroy prostate cancer tumors. It is designed for men with early-stage, low to intermediate-risk prostate cancer that hasn't spread, offering a possible alternative to surgery or radiation.
This study collects information from men with prostate cancer who are having or have had a procedure to destroy prostate tumors (ablation). It aims to track outcomes over time to improve future treatments.
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
This trial tests whether freezing only the cancer area in the prostate (focal cryotherapy) can control intermediate-risk prostate cancer. It aims to limit treatment to one tumor focus while closely checking results with targeted and follow-up testing.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.